cinacalcet ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
calcium-sensing receptors (CaSR) agonists 647 226256-56-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • cinacalcet
  • mimpara
  • cinacalcet hydrochloride
  • sensipar
  • AMG 073
  • AMG-073
  • KRN1493
  • cinacalcet HCl
Cinacalcet is a calcimimetic agent that increases the sensitivity of the calcium-sensing receptor to activation by extracellular calcium. It directly lowers PTH levels by increasing the sensitivity of the calcium sensing receptor to extracellular calcium. The reduction in PTH is associated with a concomitant decrease in serum calcium levels.
  • Molecular weight: 357.42
  • Formula: C22H22F3N
  • CLOGP: 6.35
  • LIPINSKI: 1
  • HAC: 1
  • HDO: 1
  • TPSA: 12.03
  • ALOGS: -6.81
  • ROTB: 7

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
60 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.10 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 7.19 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 20 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 17.60 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 18.30 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.05 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 19.90 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Oct. 22, 2004 EMA
March 8, 2004 FDA AMGEN

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hospitalisation 8449.97 21.13 2562 25060 82519 63378881
Product dose omission issue 6762.93 21.13 2814 24808 231499 63229901
Laboratory test abnormal 6192.07 21.13 1573 26049 25339 63436061
Adverse drug reaction 1182.65 21.13 611 27011 79103 63382297
Blood parathyroid hormone increased 886.97 21.13 216 27406 2822 63458578
Intentional product misuse 862.72 21.13 453 27169 60464 63400936
Blood parathyroid hormone abnormal 487.79 21.13 85 27537 147 63461253
Arteriovenous fistula site complication 332.69 21.13 70 27552 443 63460957
Hospice care 323.84 21.13 124 27498 7808 63453592
Hypocalcaemia 273.69 21.13 171 27451 31542 63429858
Death 266.66 21.13 535 27087 373846 63087554
Calciphylaxis 257.02 21.13 82 27540 2990 63458410
Living in residential institution 256.31 21.13 57 27565 483 63460917
Blood calcium increased 230.87 21.13 102 27520 9248 63452152
Adverse event 211.51 21.13 199 27423 67360 63394040
Rehabilitation therapy 206.33 21.13 60 27562 1590 63459810
Nausea 204.14 21.13 820 26802 853651 62607749
Decreased appetite 196.84 21.13 374 27248 250678 63210722
Parathyroid tumour benign 196.75 21.13 49 27573 704 63460696
Hypophagia 193.34 21.13 137 27485 31122 63430278
Malaise 174.79 21.13 484 27138 415470 63045930
Transplant 164.60 21.13 43 27579 755 63460645
Renal transplant 154.22 21.13 46 27576 1334 63460066
Blood calcium decreased 150.00 21.13 110 27512 26341 63435059
Blood calcium abnormal 149.26 21.13 44 27578 1224 63460176
Vomiting 145.06 21.13 552 27070 559065 62902335
Parathyroidectomy 131.65 21.13 29 27593 234 63461166
Blood parathyroid hormone decreased 130.29 21.13 70 27552 9721 63451679
Hungry bone syndrome 130.19 21.13 25 27597 91 63461309
Nephrogenic systemic fibrosis 126.49 21.13 54 27568 4502 63456898
Unevaluable investigation 118.51 21.13 21 27601 42 63461358
Fatigue 110.56 21.13 135 27487 887893 62573507
Peritonitis bacterial 106.98 21.13 49 27573 4830 63456570
Hypercalcaemia 105.39 21.13 92 27530 28230 63433170
Arthralgia 100.58 21.13 62 27560 569648 62891752
Rheumatoid arthritis 90.16 21.13 5 27617 253814 63207586
Brown tumour 87.83 21.13 16 27606 40 63461360
Blood phosphorus increased 86.39 21.13 37 27585 3108 63458292
Dialysis 84.33 21.13 54 27568 10373 63451027
Gastrointestinal tube insertion 81.73 21.13 27 27595 1100 63460300
Contraindicated product administered 81.49 21.13 3 27619 217645 63243755
Joint swelling 77.86 21.13 23 27599 327643 63133757
Mastication disorder 75.59 21.13 30 27592 2076 63459324
Hepatic enzyme increased 75.02 21.13 3 27619 202325 63259075
Parathyroid tumour malignant 74.40 21.13 13 27609 23 63461377
Pyrexia 73.94 21.13 58 27564 470420 62990980
Arthropathy 71.45 21.13 9 27613 234783 63226617
Hyperparathyroidism 71.12 21.13 31 27591 2718 63458682
Pain 70.42 21.13 135 27487 740493 62720907
Abdominal discomfort 70.33 21.13 301 27321 320584 63140816
Skin induration 69.51 21.13 32 27590 3191 63458209
Sinusitis 68.21 21.13 9 27613 226644 63234756
Systemic lupus erythematosus 66.08 21.13 7 27615 208911 63252489
Product use issue 65.78 21.13 9 27613 220511 63240889
Blood phosphorus abnormal 64.33 21.13 15 27607 160 63461240
Condition aggravated 57.77 21.13 54 27568 402163 63059237
Arteriovenous fistula occlusion 57.37 21.13 16 27606 363 63461037
Glossodynia 56.54 21.13 6 27616 178870 63282530
Treatment failure 55.12 21.13 10 27612 199033 63262367
Therapeutic product effect decreased 55.04 21.13 9 27613 193178 63268222
Hypervolaemia 52.01 21.13 63 27559 28350 63433050
Unevaluable event 50.95 21.13 85 27537 51301 63410099
Skin hypertrophy 50.09 21.13 26 27596 3365 63458035
Gastrostomy 48.29 21.13 16 27606 658 63460742
Skin fibrosis 47.87 21.13 17 27605 863 63460537
Blue toe syndrome 47.36 21.13 14 27608 393 63461007
Swelling 47.04 21.13 31 27591 275347 63186053
Peritonitis 46.98 21.13 47 27575 17107 63444293
Stomatitis 45.56 21.13 4 27618 138721 63322679
Enteral nutrition 45.07 21.13 9 27613 42 63461358
Parathyroid disorder 44.61 21.13 15 27607 646 63460754
Hyperphosphataemia 44.39 21.13 21 27601 2227 63459173
Skin tightness 44.22 21.13 26 27596 4290 63457110
Toxicity to various agents 43.37 21.13 27 27595 247223 63214177
Neonatal hypocalcaemia 42.85 21.13 8 27614 24 63461376
Rash 42.05 21.13 116 27506 560755 62900645
Neutropenia 42.04 21.13 12 27610 174993 63286407
Surgery 41.91 21.13 64 27558 35848 63425552
Abdominal pain upper 41.61 21.13 189 27433 206255 63255145
Weight increased 41.08 21.13 32 27590 260760 63200640
End stage renal disease 40.58 21.13 29 27593 6664 63454736
Febrile neutropenia 40.05 21.13 3 27619 118446 63342954
Product use in unapproved indication 39.96 21.13 14 27608 179066 63282334
Drug ineffective 39.93 21.13 279 27343 1044486 62416914
Wrong technique in product usage process 38.14 21.13 84 27538 62256 63399144
Wound 37.76 21.13 12 27610 163251 63298149
Injection site pain 37.07 21.13 6 27616 129794 63331606
Pelvic deformity 35.85 21.13 10 27612 227 63461173
Cerebrovascular accident 34.99 21.13 115 27507 107909 63353491
Contusion 34.74 21.13 11 27611 150033 63311367
Alopecia 34.19 21.13 59 27563 337477 63123923
Drug hypersensitivity 33.62 21.13 52 27570 310635 63150765
Thyroid operation 33.20 21.13 9 27613 183 63461217
Arteriovenous fistula site infection 32.90 21.13 7 27615 47 63461353
Neonatal cholestasis 32.78 21.13 7 27615 48 63461352
White blood cell count decreased 32.56 21.13 10 27612 139094 63322306
Peritoneal dialysis complication 32.35 21.13 14 27608 1206 63460194
Arteriovenous fistula thrombosis 31.71 21.13 9 27613 218 63461182
Hyperparathyroidism tertiary 31 21.13 6 27616 23 63461377
Wheezing 30.73 21.13 3 27619 95592 63365808
Joint contracture 30.69 21.13 15 27607 1709 63459691
Parathyroid hyperplasia 30.64 21.13 8 27614 140 63461260
Dysphagia 29.30 21.13 95 27527 88490 63372910
Alanine aminotransferase increased 29.17 21.13 5 27617 103765 63357635
Neuropathy peripheral 28.80 21.13 7 27615 113660 63347740
Musculoskeletal stiffness 28.62 21.13 23 27599 184595 63276805
Chronic kidney disease-mineral and bone disorder 28.40 21.13 7 27615 96 63461304
Arteriovenous fistula site haemorrhage 27.83 21.13 8 27614 203 63461197
Nephrocalcinosis 27.38 21.13 12 27610 1066 63460334
Treatment noncompliance 27.15 21.13 54 27568 37271 63424129
Lower respiratory tract infection 26.79 21.13 12 27610 132295 63329105
Cardiac operation 26.47 21.13 17 27605 3281 63458119
Dyspnoea 25.94 21.13 175 27447 661138 62800262
Discomfort 25.76 21.13 21 27601 167353 63294047
Shunt occlusion 25.72 21.13 10 27612 655 63460745
Thrombosis in device 25.46 21.13 16 27606 2974 63458426
Malignant neoplasm progression 25.32 21.13 3 27619 82118 63379282
Migraine 24.97 21.13 7 27615 103339 63358061
Headache 24.62 21.13 168 27454 633073 62828327
Blister 24.42 21.13 13 27609 129801 63331599
Adjusted calcium decreased 24.16 21.13 7 27615 183 63461217
Shunt stenosis 24.05 21.13 9 27613 531 63460869
Peripheral swelling 23.83 21.13 50 27572 265892 63195508
Hypersensitivity 23.81 21.13 58 27564 292627 63168773
COVID-19 23.30 21.13 10 27612 113093 63348307
Platelet count decreased 22.78 21.13 11 27611 116111 63345289
Fibrosis 22.78 21.13 17 27605 4175 63457225
High turnover osteopathy 22.73 21.13 5 27617 40 63461360
Osteoarthritis 22.05 21.13 7 27615 95336 63366064
Aspartate aminotransferase increased 22.02 21.13 6 27616 90271 63371129
Skin hyperpigmentation 21.55 21.13 19 27603 5902 63455498
Impaired healing 21.23 21.13 9 27613 102533 63358867

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product dose omission issue 7274.77 21.73 2732 19631 116979 34817589
Hospitalisation 6662.80 21.73 2127 20236 54775 34879793
Laboratory test abnormal 5869.17 21.73 1539 20824 18852 34915716
Adverse drug reaction 1025.01 21.73 457 21906 28885 34905683
Intentional product misuse 676.85 21.73 399 21964 45212 34889356
Blood parathyroid hormone increased 658.68 21.73 160 22203 1354 34933214
Blood parathyroid hormone abnormal 485.57 21.73 85 22278 77 34934491
Arteriovenous fistula site complication 378.87 21.73 82 22281 385 34934183
Hypocalcaemia 217.49 21.73 155 22208 24134 34910434
Adverse event 210.60 21.73 138 22225 18739 34915829
Transplant 210.41 21.73 57 22306 769 34933799
Blood calcium increased 209.95 21.73 81 22282 3513 34931055
Parathyroidectomy 186.11 21.73 35 22328 64 34934504
Hospice care 176.45 21.73 87 22276 6853 34927715
Blood parathyroid hormone decreased 153.31 21.73 51 22312 1429 34933139
Abdominal discomfort 153.20 21.73 190 22173 59645 34874923
Living in residential institution 152.17 21.73 39 22324 418 34934150
Blood calcium abnormal 148.45 21.73 40 22323 528 34934040
Nausea 141.55 21.73 507 21856 339401 34595167
Calciphylaxis 139.03 21.73 44 22319 1048 34933520
Blood calcium decreased 133.06 21.73 82 22281 10002 34924566
Hypophagia 132.05 21.73 115 22248 23907 34910661
Rehabilitation therapy 122.57 21.73 38 22325 844 34933724
Vomiting 112.90 21.73 381 21982 247240 34687328
Renal transplant 112.73 21.73 43 22320 1806 34932762
Parathyroid tumour benign 109.61 21.73 24 22339 120 34934448
Unevaluable investigation 103.50 21.73 18 22345 15 34934553
Death 99.64 21.73 509 21854 397540 34537028
Acute kidney injury 83.14 21.73 46 22317 304942 34629626
Hypercalcaemia 82.87 21.73 73 22290 15395 34919173
Hungry bone syndrome 80.73 21.73 17 22346 68 34934500
Toxicity to various agents 79.17 21.73 16 22347 200346 34734222
Blood phosphorus increased 77.76 21.73 53 22310 7668 34926900
Malaise 75.91 21.73 276 22087 185549 34749019
Abdominal pain upper 74.15 21.73 150 22213 71340 34863228
Neutropenia 67.42 21.73 10 22353 156768 34777800
Peritonitis bacterial 66.47 21.73 44 22319 6066 34928502
Pyrexia 64.48 21.73 71 22292 332942 34601626
Parathyroid hyperplasia 63.34 21.73 11 22352 9 34934559
Parathyroid disorder 59.16 21.73 12 22351 38 34934530
Surgery 56.96 21.73 57 22306 14100 34920468
Gastrointestinal disorder 54.17 21.73 86 22277 33862 34900706
Decreased appetite 52.45 21.73 228 22135 166164 34768404
Nephrogenic systemic fibrosis 51.38 21.73 32 22331 3973 34930595
Gastrostomy 50.71 21.73 19 22344 759 34933809
Parathyroid tumour malignant 50.02 21.73 9 22354 11 34934557
Condition aggravated 49.43 21.73 31 22332 192165 34742403
Gastrointestinal tube insertion 48.62 21.73 21 22342 1218 34933350
Drug interaction 48.44 21.73 44 22319 225902 34708666
Mastication disorder 47.14 21.73 21 22342 1312 34933256
Adjusted calcium decreased 46.37 21.73 8 22355 6 34934562
Unevaluable event 45.84 21.73 78 22285 32512 34902056
Dialysis 44.86 21.73 45 22318 11163 34923405
Blood phosphorus abnormal 42.49 21.73 11 22352 123 34934445
Treatment noncompliance 41.84 21.73 69 22294 28031 34906537
Fatigue 41.46 21.73 112 22251 370541 34564027
Disease progression 39.88 21.73 10 22353 108067 34826501
Leg amputation 39.86 21.73 22 22341 2182 34932386
Hyperparathyroidism 39.22 21.73 18 22345 1206 34933362
Gastric disorder 37.52 21.73 43 22320 12398 34922170
Platelet count decreased 37.22 21.73 15 22348 119702 34814866
Product use in unapproved indication 36.07 21.73 15 22348 117484 34817084
Overdose 34.43 21.73 8 22355 91051 34843517
Alanine aminotransferase increased 32.82 21.73 6 22357 80809 34853759
Brown tumour 31.78 21.73 5 22358 0 34934568
Dyspnoea 31.68 21.73 129 22234 376653 34557915
Drug effective for unapproved indication 31.40 21.73 20 22343 2582 34931986
White blood cell count decreased 31.26 21.73 11 22352 95434 34839134
Confusional state 30.94 21.73 28 22335 144132 34790436
Shunt stenosis 29.85 21.73 13 22350 769 34933799
Hyponatraemia 29.83 21.73 8 22355 82683 34851885
Peritonitis 29.67 21.73 44 22319 16321 34918247
Skin induration 29.66 21.73 18 22345 2133 34932435
High turnover osteopathy 29.43 21.73 5 22358 3 34934565
Haemoglobin increased 28.75 21.73 21 22342 3388 34931180
Shunt occlusion 28.52 21.73 13 22350 857 34933711
Neuropathy peripheral 28.31 21.73 9 22354 83254 34851314
Appetite disorder 27.37 21.73 18 22345 2453 34932115
Thrombocytopenia 26.27 21.73 37 22326 156210 34778358
Hyperphosphataemia 25.90 21.73 22 22341 4415 34930153
Thyroid operation 25.67 21.73 5 22358 12 34934556
Anaemia 25.65 21.73 71 22292 233264 34701304
Wrong technique in product usage process 25.53 21.73 65 22298 35921 34898647
Nephrocalcinosis 25.48 21.73 11 22352 637 34933931
Product use issue 25.02 21.73 5 22358 63211 34871357
Weight decreased 24.74 21.73 47 22316 176254 34758314
Vestibular neuronitis 24.54 21.73 8 22355 210 34934358
Hyperparathyroidism secondary 23.91 21.73 14 22349 1554 34933014
Rhabdomyolysis 23.83 21.73 7 22356 68156 34866412
Calcinosis 23.65 21.73 11 22352 760 34933808
Aspartate aminotransferase increased 23.63 21.73 7 22356 67776 34866792
Parathyroid gland enlargement 22.81 21.73 7 22356 150 34934418
Pulmonary embolism 22.32 21.73 15 22348 89731 34844837
Pancytopenia 22.23 21.73 17 22346 95140 34839428

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Laboratory test abnormal 9734.53 16.78 2293 33407 25755 79682933
Hospitalisation 5877.21 16.78 2016 33684 92220 79616468
Product dose omission issue 3036.05 16.78 1681 34019 245856 79462832
Blood parathyroid hormone increased 1060.23 16.78 257 35443 3188 79705500
Blood parathyroid hormone abnormal 761.85 16.78 134 35566 241 79708447
Arteriovenous fistula site complication 730.40 16.78 151 35549 838 79707850
Adverse drug reaction 483.32 16.78 325 35375 66067 79642621
Nausea 475.87 16.78 1203 34497 955993 78752695
Vomiting 376.65 16.78 881 34819 664947 79043741
Decreased appetite 349.00 16.78 581 35119 341837 79366851
Calciphylaxis 347.16 16.78 109 35591 3661 79705027
Living in residential institution 346.13 16.78 77 35623 633 79708055
Hypocalcaemia 331.48 16.78 231 35469 49693 79658995
Death 328.02 16.78 757 34943 565757 79142931
Rehabilitation therapy 294.55 16.78 82 35618 1795 79706893
Blood calcium increased 268.28 16.78 118 35582 10282 79698406
Parathyroid tumour benign 266.81 16.78 64 35636 755 79707933
Abdominal discomfort 233.33 16.78 409 35291 250318 79458370
Unevaluable investigation 231.42 16.78 39 35661 46 79708642
Malaise 207.20 16.78 582 35118 489287 79219401
Blood calcium abnormal 205.73 16.78 58 35642 1331 79707357
Hungry bone syndrome 203.40 16.78 40 35660 164 79708524
Renal transplant 186.94 16.78 62 35638 2485 79706203
Muscle spasms 168.85 16.78 290 35410 174440 79534248
Intentional product misuse 160.04 16.78 205 35495 94960 79613728
Blood calcium decreased 158.74 16.78 124 35576 31695 79676993
Peritonitis bacterial 158.55 16.78 80 35620 9487 79699201
Hypercalcaemia 154.36 16.78 132 35568 38298 79670390
Abdominal pain upper 143.21 16.78 312 35388 223507 79485181
Parathyroidectomy 141.68 16.78 30 35670 190 79708498
Blood parathyroid hormone decreased 140.04 16.78 76 35624 10460 79698228
Nephrogenic systemic fibrosis 133.80 16.78 62 35638 6098 79702590
Unevaluable event 130.38 16.78 142 35558 55443 79653245
Blood phosphorus increased 124.78 16.78 70 35630 10277 79698411
Parathyroid tumour malignant 113.31 16.78 20 35680 37 79708651
Hyperparathyroidism 107.83 16.78 44 35656 3180 79705508
Brown tumour 99.47 16.78 18 35682 41 79708647
Surgery 97.23 16.78 95 35605 32671 79676017
Dialysis 92.18 16.78 72 35628 18390 79690298
Adjusted calcium decreased 91.24 16.78 21 35679 204 79708484
Toxicity to various agents 86.97 16.78 40 35660 421500 79287188
Pyrexia 85.72 16.78 107 35593 678602 79030086
Skin induration 84.36 16.78 41 35659 4484 79704204
Transplant 83.93 16.78 27 35673 981 79707707
Febrile neutropenia 83.40 16.78 5 35695 230994 79477694
Parathyroid disorder 78.95 16.78 22 35678 483 79708205
Gastrointestinal tube insertion 78.53 16.78 29 35671 1601 79707087
Rheumatoid arthritis 76.84 16.78 4 35696 208466 79500222
Hypophagia 76.63 16.78 98 35602 45269 79663419
Shunt occlusion 73.35 16.78 27 35673 1477 79707211
Neutropenia 71.72 16.78 20 35680 287690 79420998
Condition aggravated 70.84 16.78 72 35628 501052 79207636
Arthralgia 70.22 16.78 92 35608 571711 79136977
Gastric disorder 69.84 16.78 85 35615 37348 79671340
Gastrostomy 67.87 16.78 24 35676 1169 79707519
Hypervolaemia 65.56 16.78 88 35612 42602 79666086
Arteriovenous fistula occlusion 63.76 16.78 19 35681 533 79708155
Joint swelling 63.31 16.78 25 35675 288621 79420067
Hyperphosphataemia 63.24 16.78 38 35662 6338 79702350
Hepatic enzyme increased 62.86 16.78 5 35695 182605 79526083
Fatigue 62.47 16.78 211 35489 929516 78779172
Blood phosphorus abnormal 60.89 16.78 16 35684 279 79708409
Shunt stenosis 60.64 16.78 23 35677 1368 79707320
Peritonitis 59.49 16.78 68 35632 27968 79680720
Skin hypertrophy 58.49 16.78 33 35667 4895 79703793
Parathyroid hyperplasia 58.37 16.78 14 35686 165 79708523
Drug interaction 58.25 16.78 60 35640 415123 79293565
Sinusitis 58.14 16.78 9 35691 195492 79513196
Contraindicated product administered 58.12 16.78 3 35697 157535 79551153
Skin tightness 57.61 16.78 34 35666 5488 79703200
Leg amputation 55.94 16.78 29 35671 3637 79705051
Product use issue 55.32 16.78 13 35687 209809 79498879
Diarrhoea 53.89 16.78 616 35084 879873 78828815
End stage renal disease 53.22 16.78 44 35656 12176 79696512
Peritoneal dialysis complication 52.08 16.78 24 35676 2330 79706358
High turnover osteopathy 50.65 16.78 10 35690 42 79708646
Arteriovenous fistula thrombosis 50.45 16.78 16 35684 555 79708133
Malignant neoplasm progression 48.90 16.78 3 35697 135987 79572701
Skin fibrosis 48.25 16.78 20 35680 1504 79707184
Pelvic deformity 45.64 16.78 10 35690 76 79708612
Product use in unapproved indication 43.97 16.78 29 35671 250330 79458358
Parathyroid gland enlargement 43.60 16.78 11 35689 162 79708526
White blood cell count decreased 43.47 16.78 15 35685 188273 79520415
Alanine aminotransferase increased 42.99 16.78 10 35690 162560 79546128
Arthropathy 42.85 16.78 13 35687 177098 79531590
Appetite disorder 42.62 16.78 32 35668 7707 79700981
Blue toe syndrome 41.83 16.78 14 35686 577 79708111
Acute kidney injury 41.16 16.78 109 35591 519295 79189393
Stomatitis 40.90 16.78 8 35692 146749 79561939
Injection site pain 40.90 16.78 5 35695 129833 79578855
Cardiac operation 39.95 16.78 26 35674 4986 79703702
Platelet count decreased 39.27 16.78 19 35681 194645 79514043
Arteriovenous fistula site infection 38.18 16.78 10 35690 172 79708516
Parathyroid haemorrhage 37.84 16.78 6 35694 3 79708685
Therapeutic procedure 37.12 16.78 14 35686 820 79707868
Intentional product use issue 37.09 16.78 11 35689 152101 79556587
Weight increased 36.74 16.78 42 35658 277344 79431344
Angina pectoris 36.33 16.78 75 35625 51657 79657031
Therapeutic product effect decreased 36.22 16.78 14 35686 163849 79544839
Arteriovenous fistula site haemorrhage 35.71 16.78 11 35689 346 79708342
Nephrocalcinosis 35.39 16.78 16 35684 1486 79707202
Wrong technique in product usage process 35.25 16.78 92 35608 73783 79634905
Treatment noncompliance 33.49 16.78 73 35627 52195 79656493
Joint contracture 32.96 16.78 18 35682 2506 79706182
Pericarditis 32.86 16.78 4 35696 104232 79604456
Treatment failure 32.37 16.78 18 35682 170468 79538220
Lower respiratory tract infection 32.14 16.78 9 35691 129211 79579477
Hyperparathyroidism secondary 32.08 16.78 18 35682 2642 79706046
Shunt infection 32.07 16.78 9 35691 203 79708485
Neuropathy peripheral 31.35 16.78 12 35688 141293 79567395
Chronic kidney disease-mineral and bone disorder 31.22 16.78 11 35689 530 79708158
Rash 30.62 16.78 144 35556 578214 79130474
Aspartate aminotransferase increased 30.38 16.78 12 35688 138629 79570059
Glossodynia 30.16 16.78 5 35695 103332 79605356
Fistula repair 30.05 16.78 7 35693 72 79708616
Arrhythmia 29.94 16.78 77 35623 61195 79647493
Cerebrovascular accident 29.73 16.78 143 35557 155149 79553539
Wheezing 29.25 16.78 8 35692 116656 79592032
Systemic lupus erythematosus 29.10 16.78 9 35691 121140 79587548
Hypotension 29.04 16.78 313 35387 440004 79268684
Thyroid operation 28.78 16.78 8 35692 174 79708514
Constipation 28.76 16.78 221 35479 282829 79425859
Haemoglobin increased 28.64 16.78 23 35677 6109 79702579
Calcinosis 28.51 16.78 16 35684 2349 79706339
Toe amputation 28.06 16.78 19 35681 3892 79704796
Blood pressure increased 27.98 16.78 32 35668 211328 79497360
Confusional state 27.28 16.78 64 35636 317933 79390755
Blood cholesterol increased 26.92 16.78 3 35697 83717 79624971
Psoriasis 26.90 16.78 4 35696 89583 79619105
Phosphaturic mesenchymal tumour 26.85 16.78 4 35696 0 79708688
Thrombosis in device 26.68 16.78 21 35679 5421 79703267
COVID-19 25.40 16.78 20 35680 157654 79551034
Parathyroid gland operation 25.33 16.78 5 35695 21 79708667
Hyperparathyroidism tertiary 25.33 16.78 5 35695 21 79708667
Hyperparathyroidism primary 25.15 16.78 9 35691 454 79708234
Fibrosis 24.98 16.78 20 35680 5289 79703399
Drug effective for unapproved indication 24.87 16.78 21 35679 5980 79702708
Alopecia 24.63 16.78 41 35659 231314 79477374
Hepatic cyst infection 24.49 16.78 7 35693 169 79708519
Swelling 24.40 16.78 37 35663 216674 79492014
Dyspnoea 24.32 16.78 256 35444 856769 78851919
Medical procedure 24.01 16.78 8 35692 325 79708363
Parathyroid tumour 24.00 16.78 6 35694 85 79708603
Pain 23.91 16.78 201 35499 703601 79005087
Hypercalciuria 23.80 16.78 9 35691 531 79708157
Mucosal inflammation 23.58 16.78 3 35697 75577 79633111
Hospice care 23.54 16.78 26 35674 10298 79698390
Drug ineffective 23.49 16.78 342 35358 1080571 78628117
Paraesthesia 23.41 16.78 147 35553 176176 79532512
Skin hyperpigmentation 23.22 16.78 22 35678 7281 79701407
Gastrointestinal disorder 23 16.78 112 35588 122093 79586595
Overdose 22.17 16.78 30 35670 184176 79524512
Blood pressure abnormal 21.34 16.78 32 35668 17137 79691551
Neoplasm malignant 21.03 16.78 45 35655 31765 79676923
Loss of personal independence in daily activities 20.70 16.78 10 35690 102570 79606118
Asthma 20.69 16.78 18 35682 135077 79573611
Intermittent claudication 20.57 16.78 15 35685 3456 79705232
Aplasia pure red cell 20.15 16.78 21 35679 7789 79700899
Parathyroid cyst 20.14 16.78 3 35697 0 79708688
Cardiac disorder 20.10 16.78 70 35630 65687 79643001
Blood bilirubin increased 19.79 16.78 3 35697 66229 79642459
Wound 19.66 16.78 14 35686 116165 79592523
Rhabdomyolysis 19.41 16.78 11 35689 103120 79605568
Blood phosphorus decreased 19.15 16.78 19 35681 6649 79702039
Extremity contracture 18.95 16.78 11 35689 1721 79706967
Renal cyst infection 18.95 16.78 6 35694 207 79708481
Oxygen saturation decreased 18.80 16.78 18 35682 129029 79579659
Foot amputation 18.74 16.78 9 35691 959 79707729
Migraine 18.48 16.78 8 35692 87485 79621203
Intracardiac mass 18.47 16.78 6 35694 225 79708463
Blood glucose decreased 18.37 16.78 38 35662 26196 79682492
Oncocytoma 18.30 16.78 4 35696 30 79708658
Pancytopenia 17.99 16.78 29 35671 165716 79542972
Nasal congestion 17.83 16.78 6 35694 76546 79632142
Vestibular neuronitis 17.78 16.78 8 35692 735 79707953
Gangrene 17.77 16.78 21 35679 8943 79699745
Poor peripheral circulation 17.60 16.78 14 35686 3669 79705019
Drug hypersensitivity 17.25 16.78 72 35628 298844 79409844
Anaphylactic reaction 17.15 16.78 8 35692 83735 79624953
Blister 17.02 16.78 17 35683 119459 79589229
Liver function test abnormal 16.97 16.78 4 35696 64471 79644217
Urticaria 16.91 16.78 36 35664 185165 79523523
Osteoarthritis 16.88 16.78 9 35691 87300 79621388

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC H05BX01 SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
CALCIUM HOMEOSTASIS
ANTI-PARATHYROID AGENTS
Other anti-parathyroid agents
FDA MoA N0000020081 Increased Calcium-sensing Receptor Sensitivity
MeSH PA D057966 Calcimimetic Agents
MeSH PA D000077264 Calcium-Regulating Hormones and Agents
MeSH PA D006727 Hormone Antagonists
FDA EPC N0000175902 Calcium-sensing Receptor Agonist
CHEBI has role CHEBI:48525 calcimimetics
CHEBI has role CHEBI:50183 P450 inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypercalcemia due to Primary Hyperparathyroidism indication
Hyperparathyroidism Secondary to Chronic Renal Failure with Dialysis indication
Parathyroid Carcinoma with Hypercalcemia indication
Hypophosphatemia contraindication 4996001
Hypocalcemia contraindication 5291005
Low blood pressure contraindication 45007003
Chronic heart failure contraindication 48447003
Seizure disorder contraindication 128613002
Disease of liver contraindication 235856003 DOID:409
Adynamic bone disease contraindication 236552002




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.69 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 30MG BASE SENSIPAR AMGEN N021688 March 8, 2004 RX TABLET ORAL 7829595 Sept. 22, 2026 METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA
EQ 60MG BASE SENSIPAR AMGEN N021688 March 8, 2004 RX TABLET ORAL 7829595 Sept. 22, 2026 METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA
EQ 90MG BASE SENSIPAR AMGEN N021688 March 8, 2004 RX TABLET ORAL 7829595 Sept. 22, 2026 METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Extracellular calcium-sensing receptor GPCR POSITIVE ALLOSTERIC MODULATOR EC50 7.70 CHEMBL CHEMBL
Cytochrome P450 2D6 Enzyme IC50 7.30 CHEMBL
Glycine receptor subunit alpha-1 Ion channel EC50 6.49 CHEMBL
Metabotropic glutamate receptor 5 GPCR ALLOSTERIC MODULATOR Ki 4.35 IUPHAR

External reference:

IDSource
4021430 VUID
N0000148841 NUI
D03504 KEGG_DRUG
364782-34-3 SECONDARY_CAS_RN
384379 RXNORM
4021430 VANDF
C1337242 UMLSCUI
CHEBI:48390 CHEBI
CHEMBL1201284 ChEMBL_ID
CHEMBL1200776 ChEMBL_ID
DB01012 DRUGBANK_ID
D000069449 MESH_DESCRIPTOR_UI
156419 PUBCHEM_CID
3308 IUPHAR_LIGAND_ID
8287 INN_ID
UAZ6V7728S UNII
18133 MMSL
303128 MMSL
49840 MMSL
d05218 MMSL
008595 NDDF
008596 NDDF
409391006 SNOMEDCT_US
409392004 SNOMEDCT_US
426512007 SNOMEDCT_US
YP4 PDB_CHEM_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Cinacalcet HUMAN PRESCRIPTION DRUG LABEL 1 0904-7067 TABLET, FILM COATED 30 mg ORAL ANDA 25 sections
Cinacalcet Human Prescription Drug Label 1 16714-078 TABLET, FILM COATED 30 mg ORAL ANDA 27 sections
Cinacalcet Human Prescription Drug Label 1 16714-078 TABLET, FILM COATED 30 mg ORAL ANDA 27 sections
Cinacalcet Human Prescription Drug Label 1 16714-079 TABLET, FILM COATED 60 mg ORAL ANDA 27 sections
Cinacalcet Human Prescription Drug Label 1 16714-079 TABLET, FILM COATED 60 mg ORAL ANDA 27 sections
Cinacalcet Human Prescription Drug Label 1 16714-080 TABLET, FILM COATED 90 mg ORAL ANDA 27 sections
Cinacalcet Human Prescription Drug Label 1 16714-080 TABLET, FILM COATED 90 mg ORAL ANDA 27 sections
CINACALCET HUMAN PRESCRIPTION DRUG LABEL 1 16729-440 TABLET, FILM COATED 30 mg ORAL ANDA 25 sections
CINACALCET HUMAN PRESCRIPTION DRUG LABEL 1 16729-441 TABLET, FILM COATED 60 mg ORAL ANDA 25 sections
CINACALCET HUMAN PRESCRIPTION DRUG LABEL 1 16729-442 TABLET, FILM COATED 90 mg ORAL ANDA 25 sections
Cinacalcet Human Prescription Drug Label 1 31722-103 TABLET, FILM COATED 30 mg ORAL ANDA 29 sections
Cinacalcet Human Prescription Drug Label 1 31722-104 TABLET, FILM COATED 60 mg ORAL ANDA 29 sections
Cinacalcet Human Prescription Drug Label 1 31722-105 TABLET, FILM COATED 90 mg ORAL ANDA 29 sections
Cinacalcet HUMAN PRESCRIPTION DRUG LABEL 1 42291-459 TABLET, FILM COATED 30 mg ORAL ANDA 25 sections
Cinacalcet HUMAN PRESCRIPTION DRUG LABEL 1 42291-459 TABLET, FILM COATED 30 mg ORAL ANDA 25 sections
Cinacalcet HUMAN PRESCRIPTION DRUG LABEL 1 42291-460 TABLET, FILM COATED 60 mg ORAL ANDA 25 sections
Cinacalcet HUMAN PRESCRIPTION DRUG LABEL 1 42291-460 TABLET, FILM COATED 60 mg ORAL ANDA 25 sections
Cinacalcet HUMAN PRESCRIPTION DRUG LABEL 1 42291-461 TABLET, FILM COATED 90 mg ORAL ANDA 25 sections
Cinacalcet HUMAN PRESCRIPTION DRUG LABEL 1 42291-461 TABLET, FILM COATED 90 mg ORAL ANDA 25 sections
Cinacalcet HUMAN PRESCRIPTION DRUG LABEL 1 42543-961 TABLET, FILM COATED 30 mg ORAL ANDA 23 sections
Cinacalcet HUMAN PRESCRIPTION DRUG LABEL 1 42543-961 TABLET, FILM COATED 30 mg ORAL ANDA 23 sections
Cinacalcet HUMAN PRESCRIPTION DRUG LABEL 1 42543-962 TABLET, FILM COATED 60 mg ORAL ANDA 23 sections
Cinacalcet HUMAN PRESCRIPTION DRUG LABEL 1 42543-962 TABLET, FILM COATED 60 mg ORAL ANDA 23 sections
Cinacalcet HUMAN PRESCRIPTION DRUG LABEL 1 42543-963 TABLET, FILM COATED 90 mg ORAL ANDA 23 sections
Cinacalcet HUMAN PRESCRIPTION DRUG LABEL 1 42543-963 TABLET, FILM COATED 90 mg ORAL ANDA 23 sections
Cinacalcet HUMAN PRESCRIPTION DRUG LABEL 1 43598-367 TABLET 30 mg ORAL ANDA 24 sections
Cinacalcet HUMAN PRESCRIPTION DRUG LABEL 1 43598-368 TABLET 60 mg ORAL ANDA 24 sections
Cinacalcet HUMAN PRESCRIPTION DRUG LABEL 1 43598-369 TABLET 90 mg ORAL ANDA 24 sections
Cinacalcet Human Prescription Drug Label 1 47335-379 TABLET, FILM COATED 30 mg ORAL ANDA 27 sections
Cinacalcet Human Prescription Drug Label 1 47335-380 TABLET, FILM COATED 60 mg ORAL ANDA 27 sections